My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Evotec Se (OP:EVOTF)

7.275 UNCHANGED
Last Price Updated: 9:51 AM EDT, Sep 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Evotec Se

Evotec Announces Progress in Strategic Neuroscience Partnership with Bristol Myers Squibb
Via ACCESSWIRE
Apple Loses Appeal Over 4G Patent Infringement In London Court, AI Can Drive TSMC's Revenue Rebound, Alibaba Conducts Strategic Review of Youku and Tudou Amidst Rivalry: Today's Top Stories
Reuters 
Via Benzinga
Evotec Secures US Government Contract For Orthopoxvirus Antibody
The U.S. 
Via Benzinga
Adapsyn Bioscience Inks Collaboration Pact With Evotec
 
Via Benzinga
The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Evotec Enters a Drug Discovery Collaboration with Janssen
HAMBURG, GERMANY / ACCESSWIRE / June 14, 2022 / Evotec SE (FRA:EVT)(MDAX/TecDAX)(ISIN:DE0005664809)(NASDAQ:EVO) announced today that the Company has entered a drug discovery collaboration with Janssen... 
From Evotec SE
Via AccessWire
Evotec and Almirall Enter into a Multi-Target Alliance in Medical Dermatology
HAMBURG, GERMANY and BARCELONA, SPAIN / ACCESSWIRE / May 19, 2022 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) and Almirall S.A. (ALM), a global... 
From Evotec AG
Via AccessWire
Evotec SE Fiscal Year 2021 Results: 'Setting the Pace' on the Data-Driven R&D Autobahn to Cures
- STRONG FINANCIAL RESULTS: 23% INCREASE IN GROUP REVENUES SIGNIFICANTLY EXCEEDING GUIDANCE - DATA-DRIVEN PLATFORMS AND TECHNOLOGIES INCREASE PROBABILITIES OF SUCCESS IN ALL MODALITIES - SUBSTANTIALLY... 
From Evotec AG
Via AccessWire
Evotec Achieves Programme Designation in Neuroscience Collaboration with Bristol Myers Squibb
- THE PROGRAMME DESIGNATION IS BASED ON AN ANTISENSE-BASED APPROACH WHICH TRIGGERS A US$ 16 M PAYMENT TO EVOTEC BY BRISTOL MYERS SQUIBB - EVOTEC SOURCES LNAPLUS(TM) ANTISENSE TECHNOLOGY THROUGH A... 
From Evotec AG
Via AccessWire
Why Are Evotec Shares Trading Lower On Friday?
Bayer AG (OTC: BAYRY) has  
Via Benzinga
Evotec Receives € 7.5 m Grant for Development of COVID-19 Therapeutic
- EVOTEC RECEIVES A € 7.5 M GRANT FROM THE GERMAN FEDERAL MINISTRY OF EDUCATION AND RESEARCH ("BMBF") FOR THE DEVELOPMENT OF A THERAPEUTIC AGAINST COVID-19 - EVOTEC IS DEVELOPING A HIGHLY POTENT... 
From Evotec AG
Via AccessWire
Germany Based Evotec Sets Terms For $576M US IPO
German biotech Evotec SE (OTC: EVTCY) plans to raise $576 million by offering 22 million ADSs at $26.16. At the proposed price, Evotec would command a market value of $... 
Via Benzinga
Pasithea, Evotec Ink Drug Development Pact
Pasithea Therapeutics Corp (NASDAQ: KTTA) has initiated a new chemical entity development program and named Evotec SE (OTC: EVOTF) its research... 
Via Benzinga
Evotec Expands Neuroscience Collaboration with Bristol Myers
Bristol Myers Squibb & Co (NYSE: BMY) has expanded its neuroscience collaboration with Evotec SE (OTC: EVTCY) to include a new cell type. Related:... 
Via Benzinga
Bristol Myers Exercises Option In-License Evotec's Neurodegenerative Candidate
Evotec SE (OTC: EVTCY) says that Bristol Myers Squibb Co (NYSE: BMY) has exercised its option to enter into an exclusive global license for EVT8683. It... 
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.